Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05862012 · ClinicalTrials.gov registry record · Phase 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Ichnos Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 11
- Study locations
NCT05862012 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by Ichnos Sciences. The registered enrollment target is 200 participants, above the 158-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (27% higher). The trial reports 11 study locations across 10 states.
The verdict
NCT05862012, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Ichnos Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
Conditions Studied
Interventions
- DRUG ISB 2001
Study Locations (11)
Victoria
- St. Vincent's Hospital Melbourne - Fitzroy
- Peter MacCallum Cancer Center - Melbourne
California
- Standford Cancer Institute - Palo Alto
Illinois
- University of Chicago Medical Center - Chicago
New York
- Montefiore Medical Center - The Bronx
North Carolina
- University of North Carolina - Chapel Hill
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
New South Wales
- Concord Hospital - Concord
Queensland
- Pindara Private Hospital - Benowa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05862012
The ClinicalTrials.gov registry entry for NCT05862012 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 158-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (27% higher). The listed sponsor is Ichnos Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which ISB 2001 is the first listed.
NCT05862012 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Victoria, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05862012 about?
NCT05862012 is a clinical study titled "Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)". This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
What is the current status of trial NCT05862012?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2023-11-01. Estimated completion is 2027-07.
What conditions does trial NCT05862012 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05862012?
The interventions under investigation include: ISB 2001 (DRUG).
Who is sponsoring clinical trial NCT05862012?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05862012 being conducted?
This trial has 11 study locations across California, Illinois, New York, North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.